Synklino Employee Directory

Biotechnology ResearchHovedstaden, Denmark11-50 Employees

Synklino is a clinical-stage biotechnology company focused on improving kidney transplant outcomes by preventing CMV infections through an ex vivo approach. Its lead program, SYN002, is delivered to the donor kidney during perfusion, targeting CMV directly in the organ and avoiding systemic therapy for the recipient. Preclinical proof-of-concept data in human donor kidneys, produced in collaboration with researchers at the University of Cambridge and Addenbrooke’s Hospital, were published in a peer-reviewed journal, and the company holds broad IP rights to SYN002 and its ex vivo use.

A Phase 1 trial is underway to evaluate safety, tolerability, and exploratory efficacy across dose cohorts in CMV-positive donor kidney recipients, led by Professor Atul Humar at the Ajmera Transplant Centre, University Health Network in Toronto. The company is based in Copenhagen, Denmark, and operates as a small to mid-sized biotechnology firm focused on transplantation-related infections. Its target customers are transplant centers and clinicians seeking to reduce CMV-related complications in kidney transplant patients to improve outcomes.

Sign up for free to view info

Company overview Email format